Viridian Therapeutics Inc Stock Price, News & Analysis

Viridian Therapeutics (NASDAQ: VRDN) has received FDA Breakthrough Therapy Designation for veligrotug, its lead drug candidate for treating Thyroid Eye Disease (TED). The designation was granted based on veligrotug's consistent improvement in diplopia and rapid proptosis response in clinical trials. The drug successfully met all primary and secondary endpoints in the THRIVE and THRIVE-2 phase 3 clinical trials for both active and chronic TED.

Notably, veligrotug is the first and only drug candidate in chronic TED to show statistically significant improvement in diplopia in a global phase 3 trial. The company plans to submit a Biologics License Application (BLA) in H2 2025, with a targeted U.S. launch in 2026. The breakthrough designation supports eligibility for Priority Review. The TED market represents significant commercial potential, with U.S. revenues of approximately $2 billion in 2024.

Viridian Therapeutics (VRDN) has granted stock options for 204,150 shares to 13 new employees as inducement awards. The options, approved on May 1, 2025, will vest over four years with 25% vesting after one year and the remainder vesting monthly over 36 months. The exercise price equals the closing price on the grant date.

The company is advancing multiple treatments for thyroid eye disease (TED), including veligrotug (VRDN-001) and VRDN-003. Both programs have shown positive results in Phase 3 trials. Additionally, Viridian is developing novel FcRn inhibitors (VRDN-006 and VRDN-008) for potential autoimmune disease treatments.

Viridian Therapeutics (Nasdaq: VRDN) has appointed Jeff Ajer to its Board of Directors. Ajer brings over 25 years of experience in rare diseases and specialty medicines commercialization, most recently serving as Executive Vice President and Chief Commercial Officer at BioMarin Pharmaceutical.

The appointment comes as Viridian advances veligrotug, its thyroid eye disease (TED) treatment candidate, towards BLA submission. The company also announced inducement grants of stock options to purchase 220,750 shares for 14 new employees, vesting over four years.

Viridian is currently conducting pivotal programs including two global phase 3 trials (THRIVE and THRIVE-2) for veligrotug, which have met all primary and secondary endpoints. Additionally, the company is advancing VRDN-003 in two phase 3 trials (REVEAL-1 and REVEAL-2) as a potential subcutaneous TED therapy, alongside developing novel FcRn inhibitors VRDN-006 and VRDN-008 for autoimmune diseases.

Viridian Therapeutics (NASDAQ: VRDN) has announced new employee stock option grants. The company approved non-qualified stock options for nine new employees totaling 113,200 shares on March 3, 2025. Additionally, newly appointed Chief Medical Officer Radhika Tripuraneni received options to purchase 310,700 shares effective March 10, 2025.

All grants will vest over four years, with 25% vesting after one year and the remainder vesting in 36 monthly installments, subject to continued employment. These inducement grants were made outside the company's Equity Incentive Plan but follow its terms and conditions.

Viridian is advancing multiple treatments for thyroid eye disease (TED), including veligrotug (VRDN-001) in two global phase 3 trials (THRIVE and THRIVE-2), which have reported positive topline data. The company is also developing VRDN-003 in two phase 3 trials (REVEAL-1 and REVEAL-2) as a potential subcutaneous TED treatment, alongside a portfolio of FcRn inhibitors (VRDN-006 and VRDN-008) for autoimmune diseases.

Viridian Therapeutics (NASDAQ: VRDN) reported significant progress in Q4 and full year 2024, highlighting positive phase 3 data for veligrotug in thyroid eye disease (TED) treatment. The company maintains a strong financial position with $717.6 million in cash as of December 31, 2024, providing runway into H2 2027.

Key developments include:

• Veligrotug BLA submission planned for H2 2025
• REVEAL-1 and REVEAL-2 phase 3 trials for VRDN-003 progressing with topline data expected in H1 2026
• VRDN-006 proof-of-concept data anticipated in Q3 2025
• VRDN-008 IND submission planned for year-end 2025

Financial results show R&D expenses increased to $238.3 million in 2024 (from $159.8M in 2023), while G&A expenses decreased to $61.1 million (from $95.0M in 2023). Net loss widened to $269.9 million for 2024 compared to $237.7M in 2023.

Viridian Therapeutics (VRDN) has announced the approval of inducement grants for 15 new employees, consisting of non-qualified stock options to purchase 527,750 shares of common stock. The grants, approved on February 3, 2025, were made outside the company's Amended and Restated 2016 Equity Incentive Plan but follow its terms.

The options' exercise price equals the closing price on the grant date and will vest over four years, with 25% vesting after one year and the remainder vesting in 36 monthly installments. The company is currently advancing multiple candidates for thyroid eye disease (TED), including veligrotug (VRDN-001) and VRDN-003, both reporting positive results in phase 3 trials. Additionally, Viridian is developing novel FcRn inhibitors VRDN-006 and VRDN-008 for potential autoimmune disease treatments.